Logo image of ANAB

ANAPTYSBIO INC (ANAB) Stock Fundamental Analysis

NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock - Currency: USD

23.83  +1.18 (+5.21%)

Fundamental Rating

4

ANAB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANAB as it has an excellent financial health rating, but there are worries on the profitability. ANAB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANAB had negative earnings in the past year.
In the past year ANAB has reported a negative cash flow from operations.
In the past 5 years ANAB always reported negative net income.
ANAB had a negative operating cash flow in each of the past 5 years.
ANAB Yearly Net Income VS EBIT VS OCF VS FCFANAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ANAB (-33.32%) is better than 63.42% of its industry peers.
ANAB has a Return On Equity of -413.34%. This is in the lower half of the industry: ANAB underperforms 76.40% of its industry peers.
Industry RankSector Rank
ROA -33.32%
ROE -413.34%
ROIC N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ANAB Yearly ROA, ROE, ROICANAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANAB Yearly Profit, Operating, Gross MarginsANAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

ANAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANAB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANAB has more shares outstanding
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANAB Yearly Shares OutstandingANAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ANAB Yearly Total Debt VS Total AssetsANAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.23, we must say that ANAB is in the distress zone and has some risk of bankruptcy.
ANAB has a Altman-Z score of -1.23. This is comparable to the rest of the industry: ANAB outperforms 58.38% of its industry peers.
There is no outstanding debt for ANAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.23
ROIC/WACCN/A
WACC8.93%
ANAB Yearly LT Debt VS Equity VS FCFANAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.25 indicates that ANAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.25, ANAB is in the better half of the industry, outperforming 71.35% of the companies in the same industry.
ANAB has a Quick Ratio of 8.25. This indicates that ANAB is financially healthy and has no problem in meeting its short term obligations.
ANAB's Quick ratio of 8.25 is fine compared to the rest of the industry. ANAB outperforms 71.53% of its industry peers.
Industry RankSector Rank
Current Ratio 8.25
Quick Ratio 8.25
ANAB Yearly Current Assets VS Current LiabilitesANAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

ANAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.01%, which is quite impressive.
The Revenue has grown by 387.16% in the past year. This is a very strong growth!
ANAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 62.73% yearly.
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
Revenue 1Y (TTM)387.16%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%286.84%

3.2 Future

The Earnings Per Share is expected to grow by 1.72% on average over the next years.
Based on estimates for the next years, ANAB will show a very strong growth in Revenue. The Revenue will grow by 23.15% on average per year.
EPS Next Y-3.83%
EPS Next 2Y1.43%
EPS Next 3Y-2.3%
EPS Next 5Y1.72%
Revenue Next Year18.63%
Revenue Next 2Y21.47%
Revenue Next 3Y13.36%
Revenue Next 5Y23.15%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ANAB Yearly Revenue VS EstimatesANAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ANAB Yearly EPS VS EstimatesANAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANAB. In the last year negative earnings were reported.
Also next year ANAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANAB Price Earnings VS Forward Price EarningsANAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANAB Per share dataANAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

ANAB's earnings are expected to decrease with -2.30% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.43%
EPS Next 3Y-2.3%

More info and screens

0

5. Dividend

5.1 Amount

ANAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAPTYSBIO INC

NASDAQ:ANAB (7/2/2025, 11:01:51 AM)

23.83

+1.18 (+5.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners133.97%
Inst Owner Change11.85%
Ins Owners1.98%
Ins Owner Change2.17%
Market Cap700.13M
Analysts83.33
Price Target43.45 (82.33%)
Short Float %32.82%
Short Ratio15.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.14%
Min EPS beat(2)-0.12%
Max EPS beat(2)56.4%
EPS beat(4)2
Avg EPS beat(4)4.73%
Min EPS beat(4)-69.51%
Max EPS beat(4)56.4%
EPS beat(8)5
Avg EPS beat(8)6.9%
EPS beat(12)6
Avg EPS beat(12)-4.85%
EPS beat(16)8
Avg EPS beat(16)-4.66%
Revenue beat(2)2
Avg Revenue beat(2)261.21%
Min Revenue beat(2)78.26%
Max Revenue beat(2)444.15%
Revenue beat(4)3
Avg Revenue beat(4)198.72%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)444.15%
Revenue beat(8)7
Avg Revenue beat(8)150.54%
Revenue beat(12)7
Avg Revenue beat(12)81.44%
Revenue beat(16)9
Avg Revenue beat(16)62.86%
PT rev (1m)13.9%
PT rev (3m)14.52%
EPS NQ rev (1m)3.32%
EPS NQ rev (3m)-6.52%
EPS NY rev (1m)-1.83%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)17.26%
Revenue NY rev (1m)19.68%
Revenue NY rev (3m)76.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.26
P/FCF N/A
P/OCF N/A
P/B 20.58
P/tB 20.58
EV/EBITDA N/A
EPS(TTM)-4.85
EYN/A
EPS(NY)-5.06
Fwd EYN/A
FCF(TTM)-3.72
FCFYN/A
OCF(TTM)-3.7
OCFYN/A
SpS3.81
BVpS1.16
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.32%
ROE -413.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.09%
ROA(5y)-20.21%
ROE(3y)-146.58%
ROE(5y)-92.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 62.14%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.25
Quick Ratio 8.25
Altman-Z -1.23
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)78.6%
Cap/Depr(5y)111.71%
Cap/Sales(3y)2.86%
Cap/Sales(5y)2.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
EPS Next Y-3.83%
EPS Next 2Y1.43%
EPS Next 3Y-2.3%
EPS Next 5Y1.72%
Revenue 1Y (TTM)387.16%
Revenue growth 3Y13.05%
Revenue growth 5Y62.73%
Sales Q2Q%286.84%
Revenue Next Year18.63%
Revenue Next 2Y21.47%
Revenue Next 3Y13.36%
Revenue Next 5Y23.15%
EBIT growth 1Y35.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.57%
EBIT Next 3Y6.55%
EBIT Next 5YN/A
FCF growth 1Y-40.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41%
OCF growth 3YN/A
OCF growth 5YN/A